456 related articles for article (PubMed ID: 23783005)
1. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Hubble J; Schwab J; Hubert C; Abbott CC
Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
[TBL] [Abstract][Full Text] [Related]
2. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
3. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
[TBL] [Abstract][Full Text] [Related]
4. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
5. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
6. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of focal dystonia with botulinum toxin A].
Sojer M; Wissel J; Müller J; Poewe W
Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
[TBL] [Abstract][Full Text] [Related]
9. [Frequency of side effects after botulinum toxin A injections in neurology, rehabilitation and gastroenterology].
Sławek J; Madaliński MH; Maciag-Tymecka I; Duzyński W
Pol Merkur Lekarski; 2005 Mar; 18(105):298-302. PubMed ID: 15997637
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
11. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin A (Dysport®): in dystonias and focal spasticity.
Keam SJ; Muir VJ; Deeks ED
Drugs; 2011 May; 71(8):1043-58. PubMed ID: 21668041
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
14. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of botulinum toxin in neurological indications.
Ward AB; Molenaers G; Colosimo C; Berardelli A
Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm.
Tsai CP; Chiu MC; Yen DJ; Guo YC; Yuan CL; Lee TC
Acta Neurol Taiwan; 2005 Jun; 14(2):61-8. PubMed ID: 16008164
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes.
Hu GC; Chuang YC; Liu JP; Chien KL; Chen YM; Chen YF
Clin Rehabil; 2009 Jan; 23(1):64-71. PubMed ID: 19114438
[TBL] [Abstract][Full Text] [Related]
18. [Indications and management of botulinum toxin].
Singer C
Rev Neurol; 1999 Jul 16-31; 29(2):157-62. PubMed ID: 10528331
[TBL] [Abstract][Full Text] [Related]
19. A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
Med Lett Drugs Ther; 2010 Nov; 52(1351):90-1. PubMed ID: 21068703
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German-Austrian open-label post-marketing surveillance prospective study.
Jost WH; Hefter H; Reissig A; Kollewe K; Wissel J
J Neurol Sci; 2014 Feb; 337(1-2):86-90. PubMed ID: 24361062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
